One of my favourite molecules.
chatGPT:
Summary
This is a narrative review of melatonin’s role in circadian rhythm regulation and brain health. The paper argues that melatonin is not just a sleep hormone, but a pleiotropic neuroprotective molecule acting through circadian, antioxidant, anti-inflammatory, mitochondrial, immune, and possibly anti-aging mechanisms. It covers insomnia, depression, Alzheimer’s disease, Parkinson’s disease, cerebral ischemia-reperfusion injury, brain aging, and dietary or supplement sources of melatonin.
The authors describe melatonin synthesis as light-dependent and controlled by the suprachiasmatic nucleus, with signalling from the retina to the pineal gland. Tryptophan is converted through serotonin and N-acetylserotonin to melatonin, mainly via AA-NAT and HIOMT enzymes. The paper links circadian disruption from light exposure, shift work, sleep disruption, and staying up late to insomnia, mood disorders, metabolic disease, cardiovascular disease, neurodegeneration, cancer, and aging.
The strongest clinical evidence presented is for insomnia and circadian rhythm disorders. The review states that melatonin and melatonin receptor agonists can improve sleep latency, total sleep time, and sleep quality, especially in older adults and some paediatric neurodevelopmental groups. However, it notes heterogeneity in dose, formulation, study duration, and population.
For depression, the paper is more cautious. It discusses melatonin’s potential effects through sleep/circadian regulation, HPA-axis modulation, mitochondrial function, and inflammatory pathways, but much of the clinical evidence comes from comorbid populations such as PCOS, diabetes, or dialysis rather than primary major depressive disorder.
For Alzheimer’s disease, the paper presents melatonin as potentially useful for sleep disturbance, early disease, oxidative stress, tau phosphorylation, amyloid aggregation, pineal dysfunction, and gut microbiome changes. The evidence is described as mixed and mostly from small or short clinical trials plus animal and mechanistic work.
For Parkinson’s disease, the paper mainly supports melatonin for sleep quality, REM sleep behaviour disorder, oxidative stress markers, mitochondrial activity, pain, and circadian regulation. It does not show convincing evidence that melatonin improves core motor features or slows disease progression.
For cerebral ischemia-reperfusion injury, the review highlights mechanisms including Nrf2/HO-1 activation, RORα signalling, reduced inflammatory cytokines, reduced oxidative stress, and NLRX1-linked mitophagy. However, the human evidence is very limited, with the paper itself describing the field as largely preclinical.
For brain aging, the paper emphasizes SIRT1/FOXO3a, mitochondrial membrane potential, cardiolipin preservation, reduced mitochondrial ROS, and reduced microglial activation. Again, the evidence is mainly animal-based, with no large primary prevention trials in healthy older adults.
The paper also discusses dietary melatonin from foods such as milk, fish, eggs, grapes, cherries, strawberries, tomatoes, peppers, pistachios, coffee, and some herbs. It also reviews supplements, noting wide variation in supplement content and regulatory differences between countries. It recommends low-dose use, generally 0.5–5 mg, limiting continuous use unless medically supervised, and preferring dietary sources for long-term use.
Claimed novelty
The novelty is not that melatonin is neuroprotective; that is already a large field. The paper’s novelty is mainly integrative and translational:
| Area | What is relatively novel or useful |
|---|---|
| Cross-condition comparison | It brings insomnia, depression, AD, PD, cerebral ischemia, and brain aging into one framework. |
| Evidence grading | It explicitly distinguishes stronger clinical evidence for insomnia from weaker/preclinical evidence for cerebral ischemia and brain aging. |
| Mechanistic synthesis | It combines receptor-mediated effects, direct radical scavenging, Nrf2/HO-1, NF-κB, NLRP3, RORα, mitophagy, SIRT1/FOXO3a, and mitochondrial pathways. |
| Food/supplement angle | It connects neuroprotection with functional foods, melatonin-rich diets, supplement quality, and regulation. |
| Cautionary tone | It repeatedly notes small sample sizes, short follow-up, dose heterogeneity, and lack of disease-modifying proof. |
The most useful part of the review is probably Table 1, where the authors summarise the evidence strength: insomnia is “strong”; depression, Alzheimer’s disease, and Parkinson’s disease are “moderate”; cerebral ischemia and brain aging are “preliminary.” This helps prevent overclaiming, even though the review is generally favourable to melatonin.
Critique
The paper is useful as a broad map, but it is not a systematic review. The authors say they searched PubMed, Web of Science, and Google Scholar and excluded preprints, conference abstracts, and non-English articles, but they did not perform formal risk-of-bias assessment or meta-analysis. They acknowledge that the synthesis is qualitative and may be subject to selection bias.
A major weakness is that the paper sometimes moves too easily from mechanism to therapeutic implication. Melatonin has many plausible mechanisms: antioxidant effects, mitochondrial effects, inflammation suppression, circadian signalling, autophagy/mitophagy, and SIRT1-related pathways. But pleiotropy does not prove clinical efficacy. In several sections, mechanistic plausibility is stronger than clinical evidence.
The review’s own evidence hierarchy shows the central problem: apart from insomnia, most conditions rely on small trials, short durations, biomarkers, animal models, or surrogate outcomes. The authors themselves note that neurodegenerative disease studies suggest possible effects on sleep and biomarkers, but disease-modifying effects remain unproven; brain aging lacks large prevention trials; and ischemia evidence is mostly preclinical.
The section on dietary sources and functional foods is interesting but somewhat speculative. Foods containing melatonin are not equivalent to pharmacological melatonin supplementation. Bioavailability, dose, timing, metabolism, food matrix effects, and inter-individual variability are not resolved. The discussion of melatonin-containing household items such as masks, soaps, pillows, aromatherapy capsules, and pendants seems especially weak unless supported by strong absorption and outcome data.
The regulatory table is useful, but the paper should be read cautiously here. Melatonin’s classification and availability can change by jurisdiction, and terms such as “pharmacy medicine,” “prescription drug,” or “low-dose OTC” can hide important details about age, indication, dose, and formulation.
The supplement safety discussion is balanced in one respect: it says evidence does not support classic dependence or withdrawal like benzodiazepines or Z-drugs. However, the paper also raises a theoretical concern about long-term high-dose use downregulating endogenous synthesis. That concern is plausible but appears less clinically established than the paper’s practical recommendations might imply.
Bottom line
This is a broad, useful, pro-melatonin narrative review. Its strongest conclusion is that melatonin has credible clinical value for sleep and circadian rhythm regulation. Its more ambitious claims—neuroprotection in Alzheimer’s, Parkinson’s, stroke, and brain aging—are mechanistically plausible but not yet clinically proven. The paper’s best feature is that it acknowledges the uneven evidence base; its main weakness is that, despite this caution, it sometimes presents food, supplements, and functional-product development as more ready for translation than the clinical evidence justifies.